Zhu Jie, Yang Li-Kun, Chen Wei-Liang, Lin Wei, Wang Yu-Hai, Chen Tao
Department of Neurosurgery, The 101th Hospital of PLA, School of Medicine, Anhui Medical University, Wuxi, China.
Front Pharmacol. 2019 Apr 2;10:325. doi: 10.3389/fphar.2019.00325. eCollection 2019.
Spinal cord ischemia-reperfusion injury (SCI/R) is a rare but devastating disorder with a poor prognosis. Small conductance calcium-activated K (SK/K) channels are a family of voltage-independent potassium channels that are shown to participate in the pathological process of several neurological disorders. The aim of this study was to investigate the role of SK/K channels in experimental SCI/R in rabbits. The expression of SK/K1 protein significantly decreased in both cytoplasm and mitochondria in spinal cord tissues after SCI/R. Treatment with 2 mg/kg NS309, a pharmacological activator for SK/K channel, attenuated SCI/R-induced neuronal loss, spinal cord edema and neurological dysfunction. These effects were still observed when the administration was delayed by 6 h after SCI/R initiation. NS309 decreased the levels of oxidative products and promoted activities of antioxidant enzymes in both serum and spinal cord tissues. The results of ELISA assay showed that NS309 markedly decreased levels of pro-inflammatory cytokines while increased anti-inflammatory cytokines levels after SCI/R. In addition, treatment with NS309 was shown to preserve mitochondrial respiratory complexes activities and enhance mitochondrial biogenesis. The results of western blot analysis showed that NS309 differentially regulated the expression of mitochondrial dynamic proteins. In summary, our results demonstrated that the SK/K channel activator NS309 protects against SCI/R via anti-oxidative activity and inhibition of mitochondrial dysfunction, indicating a therapeutic potential of NS309 for SCI/R.
脊髓缺血再灌注损伤(SCI/R)是一种罕见但具有毁灭性的疾病,预后较差。小电导钙激活钾(SK/K)通道是一类电压非依赖性钾通道,已被证明参与多种神经系统疾病的病理过程。本研究旨在探讨SK/K通道在兔实验性SCI/R中的作用。SCI/R后,脊髓组织细胞质和线粒体中SK/K1蛋白的表达均显著降低。用2mg/kg的SK/K通道药理学激活剂NS309治疗,可减轻SCI/R诱导的神经元丢失、脊髓水肿和神经功能障碍。在SCI/R开始后延迟6小时给药时,仍可观察到这些效果。NS309降低了血清和脊髓组织中氧化产物的水平,并促进了抗氧化酶的活性。ELISA检测结果显示,SCI/R后NS309显著降低促炎细胞因子水平,同时提高抗炎细胞因子水平。此外,NS309治疗可维持线粒体呼吸复合物的活性并增强线粒体生物发生。蛋白质印迹分析结果表明,NS309对线粒体动态蛋白的表达有不同的调节作用。总之,我们的结果表明,SK/K通道激活剂NS309通过抗氧化活性和抑制线粒体功能障碍来保护免受SCI/R的影响,表明NS309对SCI/R具有治疗潜力。
Front Cell Dev Biol. 2021-2-18
Drug Discov Today. 2016-6-17
World J Emerg Med. 2011
Asian Cardiovasc Thorac Ann. 2015-2
Cell Death Dis. 2014-1-16
Ann Cardiothorac Surg. 2012-9
Mediators Inflamm. 2013-7-14
Curr Pharm Des. 2013